just a heads-up for anyone on compounded tirzepatide, the fda officially took mounjaro and zepbound off the drug shortage list as of a few days ago. i’ve been tracking this because i started on compounded, and this is the regulatory change we knew was coming. the legal standing for most 503a pharmacies to compound tirzepatide was based on that shortage declaration. without it, the primary justification is gone.
this doesn’t mean every supply will vanish overnight. i’m sure some pharmacies will try to argue a specific presentation is still unavailable or find other loopholes. but the broad-stroke allowance just ended. for anyone who relies on a compounded source, this is probably the moment to get a concrete plan b and c in place.
that could mean starting the prior authorization fight for branded, looking into appeals, or finding a prescriber who works with a legitimate 503b outsourcing facility. the 503b rules are different, but that’s its own conversation about vetting fda inspection records. the main thing is not to get caught with no refills and have to stop cold. a sudden interruption is what messes with the metabolic numbers more than anything.
hmm thank you for posting this, it’s a really important flag for people. That “sudden interruption” you mentioned is the whole story; the dose gap while someone fights for a new script is a much bigger metabolic confound than the switch from compounded to branded ever was for me.
good call on this, the writing’s been on the wall for a while. “a sudden interruption is what messes with the metabolic numbers more than anything” is right, but how much depends on where someone is in their injection week
“a sudden interruption is what messes w/ the metabolic numbers more than anything,” and the impact of that really varies by where someone is in their dose cycle. Someone who injected three days ago has a very different decay curve to manage than someone who’s eight days out when supply finally runs dry
The “sudden interruption is what messes with the metabolic numbers” part is the whole conversation. It’s not just about appetite or weight, it’s the metabolic whiplash when the primary tool managing your fasting insulin is suddenly removed. For anyone with PCOS or IR, that’s a significant physiological event. fwiw, the unwelcome side effect of this is that it forces the consistency question. The batch-to-batch variance from some 503a suppliers was its own kind of metabolic rollercoaster. Knowing the concentration is what the label says it is, every single time, is a variable I won’t mind removing. Now the problem just shifts from vetting a pharmacy to fighting the PA process. And if everyone on compounded successfully switches to branded Mounjaro or Zepbound, that will just create the next shortage. The system can’t actually handle the demand. 🤔
hmm knowing this is coming for compounded tirz is a huge thing for anyone managing a metabolic condition long-term. the “sudden interruption” you mentioned truly is the biggest concern, bc getting our fasting insulin back into a good range